AR085633A1 - Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos - Google Patents
Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenosInfo
- Publication number
- AR085633A1 AR085633A1 ARP120100760A ARP120100760A AR085633A1 AR 085633 A1 AR085633 A1 AR 085633A1 AR P120100760 A ARP120100760 A AR P120100760A AR P120100760 A ARP120100760 A AR P120100760A AR 085633 A1 AR085633 A1 AR 085633A1
- Authority
- AR
- Argentina
- Prior art keywords
- coadyuvants
- antigens
- antibodies
- cells presenting
- directly directed
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000002689 Toll-like receptor Human genes 0.000 abstract 2
- 108020000411 Toll-like receptor Proteins 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Composiciones y métodos para mejorar la respuesta inmune. En particular, se provee una composición coadyuvante que comprende un anticuerpo específico contra las células dendríticas (DC), o un fragmento de éste, conjugado con al menos una porción de un agonista de un receptor tipo Toll (TLR), más específicamente un ligando de TLR7 (TLR7L), y un vehículo farmacéuticamente aceptable, donde el conjugado y el agonista están presentes en una cantidad combinada que es eficaz para provocar una respuesta inmune en el sujeto humano o animal cuyo sistema inmune se desea estimular.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161450480P | 2011-03-08 | 2011-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085633A1 true AR085633A1 (es) | 2013-10-16 |
Family
ID=46795779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100760A AR085633A1 (es) | 2011-03-08 | 2012-03-08 | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120231023A1 (es) |
AR (1) | AR085633A1 (es) |
TW (1) | TW201247706A (es) |
WO (1) | WO2012122396A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
US9045542B2 (en) | 2011-08-29 | 2015-06-02 | Baylor Research Institute | Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2) |
CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN102993265B (zh) * | 2012-10-10 | 2015-05-13 | 深圳大学 | 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物 |
GB201220010D0 (en) * | 2012-11-07 | 2012-12-19 | Oxford Biotherapeutics Ltd | Therapeutic amd diagnostic target |
AU2014302082B2 (en) | 2013-06-28 | 2019-08-08 | Baylor Research Institute | Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis |
DK3055331T3 (da) | 2013-10-11 | 2021-03-22 | Oxford Bio Therapeutics Ltd | Konjugerede antistoffer mod ly75 til cancerbehandling |
EP3092255A4 (en) | 2014-01-10 | 2017-09-20 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating egfr expressing tumors |
JP7037884B2 (ja) | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | Hpv及びhpv関連疾患に対する新規のワクチン |
WO2015175957A1 (en) * | 2014-05-16 | 2015-11-19 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
US20170095573A1 (en) * | 2014-06-02 | 2017-04-06 | Baylor Research Institute | Methods and compositions for treating allergy and inflammatory diseases |
RU2016151645A (ru) | 2014-07-01 | 2018-08-03 | Пфайзер Инк. | Биспецифические гетеродимерные диантитела и их применение |
JP6760919B2 (ja) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 腫瘍を治療するための抗pd−l1組み合わせ |
CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于***的抗-pd-l1结合物 |
SG11201710734UA (en) * | 2015-06-24 | 2018-01-30 | Japan Chem Res | Anti-human transferrin receptor antibody permeating blood-brain barrier |
EP3315515A4 (en) | 2015-06-24 | 2019-06-05 | JCR Pharmaceuticals Co., Ltd. | HYBRID PROTEIN CONTAINING A BDNF |
MA44334A (fr) * | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
GB2552041A (en) * | 2015-12-07 | 2018-01-10 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct-agonist conjugates and methods thereof |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-egfr组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-cd20组合 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于***的抗-her2组合 |
MY191649A (en) | 2016-03-04 | 2022-07-05 | Jn Biosciences Llc | Antibodies to tigit |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
KR102497564B1 (ko) | 2016-12-26 | 2023-02-07 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체 |
EP3574018A4 (en) * | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
AR111651A1 (es) * | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
WO2018232725A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
CA3088710C (en) * | 2018-01-18 | 2023-12-12 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Langerin+ cell targeting |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
US20230348468A1 (en) | 2020-01-27 | 2023-11-02 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
WO2021154661A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
WO2021154667A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
CN115279765A (zh) | 2020-01-27 | 2022-11-01 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
JP2023512227A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
JP2023512228A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
WO2021154662A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
JP2023512207A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
WO2021154665A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
BR112022024221A2 (pt) | 2020-06-02 | 2022-12-20 | Arcus Biosciences Inc | Anticorpos para tigit |
CN116209678A (zh) | 2020-07-01 | 2023-06-02 | 安尔士制药公司 | 抗asgr1抗体缀合物及其用途 |
CN111850007B (zh) * | 2020-07-27 | 2022-03-29 | 齐鲁工业大学 | 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36864及应用 |
JP2023549555A (ja) * | 2020-11-18 | 2023-11-27 | パイオニア イミュノセラピューティクス インコーポレイテッド | 抗marco抗体及びその使用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69817393T2 (de) * | 1997-11-28 | 2004-06-17 | Sumitomo Pharmaceuticals Co., Ltd. | Neue heterozyklische verbindungen |
EP1931352B1 (en) * | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
EP2129773B1 (en) * | 2007-02-23 | 2013-02-13 | Baylor Research Institute | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 |
KR101548143B1 (ko) * | 2008-07-16 | 2015-08-28 | 베일러 리서치 인스티튜트 | 극대화된 Gag 및 Nef를 수지상 세포에 표적화시킴을 기본으로 하는 HIV 백신 |
BRPI1008383A2 (pt) * | 2009-02-11 | 2016-02-23 | Univ California | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto |
CN102741295A (zh) * | 2009-03-10 | 2012-10-17 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
CA3032548C (en) * | 2009-03-10 | 2023-05-09 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
JP5986382B2 (ja) * | 2009-03-10 | 2016-09-06 | ベイラー リサーチ インスティテュートBaylor Research Institute | 抗原提示細胞ターゲティング癌ワクチン |
TWI506035B (zh) * | 2010-08-13 | 2015-11-01 | Baylor Res Inst | 以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑 |
-
2012
- 2012-03-08 US US13/415,564 patent/US20120231023A1/en not_active Abandoned
- 2012-03-08 TW TW101107940A patent/TW201247706A/zh unknown
- 2012-03-08 WO PCT/US2012/028317 patent/WO2012122396A1/en active Application Filing
- 2012-03-08 AR ARP120100760A patent/AR085633A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20120231023A1 (en) | 2012-09-13 |
WO2012122396A1 (en) | 2012-09-13 |
TW201247706A (en) | 2012-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR085633A1 (es) | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos | |
MX2013001527A (es) | Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos. | |
MX363307B (es) | Plataformas para suministro de antigenos. | |
WO2008039874A3 (en) | Cancer stem cell antigen vaccines and methods | |
MX2010001054A (es) | Composiciones adyuvantes antigenicas y metodos. | |
DOP2013000128A (es) | Uso de células t modificadas con un receptor de antígeno quimérico para tratar el cáncer | |
MX2013013111A (es) | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. | |
GB2505857A (en) | Vaccine adjuvant composition comprising inulin particles | |
MX2020011781A (es) | Formulacion arn para inmunoterapia. | |
CL2014000786A1 (es) | Composicion que comprende un péptido que se une de manera inmunoespecífica a la secuencia a relacionada con el polipeptido mhc de clase i (mica); método para obtener células inmunes dirigidas contra un antígeno propio de un individuo. | |
PH12015501519A1 (en) | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant | |
BRPI0510430A (pt) | composições e métodos para vacinação mucosal | |
MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
BR112013027508A2 (pt) | nanotransportadores sintéticos tolerogênicos para reduzir respostas de anticorpos | |
TR201908367T4 (tr) | Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
AR101455A1 (es) | Molécula portadora | |
WO2013009475A8 (en) | Photosensitizing antibody-fluorophore conjugates | |
CR20110316A (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la función de células t | |
MX2009008140A (es) | Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno. | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
AR079556A1 (es) | Formacion de anticuerpos | |
CO6511229A2 (es) | Metodos para reducir la actividad viricida en composiciones pcv-2 y composiciones pcv-2 con una inmunogeicidad mejorada | |
AR082630A1 (es) | Anticuerpos anti-tenascina-c a2 y metodos de uso | |
CU23759A3 (es) | Composiciones inmunogénicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |